Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 02, 2023

BUY
$14.15 - $22.03 $1.63 Million - $2.54 Million
115,468 Added 337.3%
149,701 $2.84 Million
Q4 2022

Feb 01, 2023

SELL
$5.52 - $12.73 $31,463 - $72,561
-5,700 Reduced 14.27%
34,233 $435,000
Q3 2022

Nov 10, 2022

BUY
$3.02 - $7.0 $120,597 - $279,531
39,933 New
39,933 $285,000

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $415M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Bank Of Montreal Portfolio

Follow Bank Of Montreal and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.